Healthy Returns: Ozempic, Wegovy linked to rare cases of serious eye condition
The weekly injections may, in very rare cases, cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said Friday. It's the first time a regulator has confirmed the side effect following previous studies in Type 2 diabetes patients linking Ozempic to the condition, known as non-arteritic anterior ischemic optic neuropathy (NAION).
The committee has asked Novo Nordisk to add the eye condition as a side effect of "very rare" frequency in the product information for drugs that contain semaglutide. That's the active ingredient in Wegovy, Ozempic and Novo Nordisk's diabetes pill Rybelsus.
It's the latest potential concern about popular GLP-1s such as Ozempic and Wegovy, which mimic gut hormones to regulate blood sugar and tamp down appetite. Demand for the drug class has soared despite hefty price tags and a handful of unpleasant side effects that are most commonly gastrointestinal, such as nausea and vomiting.
It likely won't be a big concern for the vast majority of patients: the eye condition may affect up to 1 in 10,000 people taking semaglutide for at least one year, according to the committee.
The committee said people with diabetes who are exposed to semaglutide are at a twofold increase in the risk of developing NAION compared with those not taking it.
The eye condition is the second-most common cause of blindness due to optic nerve damage, after glaucoma. It is characterized by vision loss due to decreased blood flow to the front part of the optic nerve, which connects the eye to the brain. The disease typically occurs without any pain and most commonly affects people ages 50 and above.
The committee said patients should stop treatment with semaglutide products if they experience the side effect. Since December, it has been reviewing the findings of two Danish studies linking Ozempic to the condition in diabetes patients.
In a statement, Novo Nordisk said it has concluded that the data "did not suggest a reasonable possibility of a causal relationship between semaglutide and NAION." The company said the benefits of semaglutide still outweigh its risks.
But the drugmaker said it will collaborate with the EMA to update the labels for semaglutide products.
A day before the committee's statement, GLP-1s faced scrutiny over another potential eye-related side effect.
A study, published Thursday in JAMA Ophthalmology and conducted by University of Toronto researchers, found that diabetes patients who use GLP-1 drugs were twice as likely to develop neovascular age-related macular degeneration (nAMD) compared to those who don't take the medications.
The study also found that the longer patients were treated with these medications, the greater their risk of developing nAMD.
nAMD, commonly known as "wet" AMD, is the less common but more aggressive form of age-related macular degeneration. It is the leading cause of irreversible vision loss among older adults in the U.S.
The researchers drew on health records from Ontario, Canada. They analyzed nearly 140,000 adults with Type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD. In the vast majority of cases, patients received semaglutide.
Novo Nordisk said semaglutide's "efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes."
Feel free to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.
The 2025 CNBC Disruptor 50 list is here, and a number of health tech startups including Transcarent, Abridge and Rad AI made the cut this year.
The Disruptor 50 designation is a ranked list of innovative private companies that are advancing breakthrough technology within their sector. Any private, independently owned startups that were founded after Jan. 1, 2010 were able to be nominated.
Nominated companies had to submit qualitative information, like descriptions of their core business model, which were assessed by a team of CNBC editorial staff. They also had to submit quantitative data, like sales and user numbers, which were evaluated by CNBC's Disruptor 50 Advisory Board and Disruptor 50 VC Advisory Board.
Here are the health tech companies that earned a spot this year:
Perhaps unsurprisingly, some of the major players in AI took the top five spots on this year's list. Anduril, an autonomous defense company, earned the first spot, followed by OpenAI, Databricks, Anthropic and the design platform Canva.
Taken together, these five companies have a combined valuation of just under $500 billion, which is more than the combined total valuation of almost every past Disruptor 50 list of the last 12 years. A sign of the times, no doubt.
Feel free to send any tips, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
7 minutes ago
- CNBC
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
AstraZeneca on Monday said it plans to invest $50 billion in bolstering its U.S. manufacturing and research capabilities by 2030, becoming the latest pharmaceutical firm to ramp up its stateside spending in the wake of U.S. trade tariffs. The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill. The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca's largest single manufacturing investment in the world and will "leverage AI, automation and data analytics to optimize production," the company said. The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create "tens of thousands of jobs," AstraZeneca added. CEO Pascal Soriot said the commitment underpins the firm's "belief in America's innovation in biopharmaceuticals" and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S. AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company's annual revenues in 2024. In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets. AstraZeneca is the most valuable business listed on London's FTSE 100. The company declined to comment on the Times report. AstraZeneca's funding announcement follows similar moves by global pharmaceutical firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — who have all vowed over recent months to ramp up their U.S. investment amid U.S. President Donald Trump's demands to reshore domestic manufacturing. The industry is awaiting further clarity on the Trump administration's pharma tariffs, with the final outcome of a Section 232 investigation into the sector due at the end of this month. An effort to rebalance U.S. drug prices with those paid by other countries is also underway. Trump earlier this month suggested that the industry could face levies of up to 200%, with a brief 12-18 month grace period to allow firms to relocate manufacturing stateside. However, many firms and analysts have dubbed the time frame as insufficient. "Typically for most medicines it's a three to four year horizon. We're working very hard to accelerate that as fast as we can and demonstrate we're making the investments we have planned," Novartis CEO Vas Narasimhan said last week during an earnings call, adding that he hoped the administration would make allowances.
Business Insider
an hour ago
- Business Insider
HIMS Lawsuit Alert! Hims & Hers Faces Class Action Lawsuit After Wegovy Scandal
A class action lawsuit was filed against Hims & Hers (HIMS) by Levi & Korsinsky on June 25, 2025. The plaintiffs (shareholders) alleged that they bought HIMS stock at artificially inflated prices between April 29, 2025, and June 22, 2025 (Class Period) and are now seeking compensation for their financial losses. Investors who bought Hims & Hers stock during that period can click here to learn about joining the lawsuit. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Hims & Hers is an American telehealth platform that connects consumers with licensed healthcare professionals and medical treatments. Through the digital platform, consumers can obtain prescription medications, over-the-counter treatments, personal care products, and supplements. The company recently partnered with pharmaceutical giant Novo Nordisk (NVO) to offer its U.S. FDA-approved weight-loss drug Wegovy on the Hims & Hers platform. The company's claims about its partnership with Novo Nordisk and its future potential are at the heart of the current complaint. Hims & Hers' Misleading Claims According to the lawsuit, HIMS and two of its senior officers (the Defendants) repeatedly made false and misleading public statements throughout the Class Period. In particular, they are accused of omitting truthful information about the GLP-1 (glucagon-like peptide-1) injectables it makes available to consumers, and ancillary issues, from SEC filings and related material. During the Class Period, Hims & Hers announced that it had partnered with Novo Nordisk and that American consumers could start accessing 'NovoCare Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership.' This offering included 24/7 care, continued clinical support, and nutrition guidance, all under one roof. HIMS also noted that patients can access all dose strengths of Wegovy in a high-quality pen, available for self-pay patients (without insurance or government aid). Furthermore, in a shareholder letter issued on May 5, 2025, Hims expressed excitement over its 'innovative partnerships' that offer consumers greater choice within the weight-loss category. The company also highlighted its long-term collaboration with Novo Nordisk to expand affordable access to proven obesity care. This partnership was touted as a way to strengthen the platform's offerings with Novo Nordisk's innovative pipeline, enabling Hims to serve more customers, expand access to clinically proven treatments, and drive stronger health outcomes. Finally, in its Q1FY25 quarterly report filed on May 5, Hims & Hers stated that its GLP-1 offerings generated about $230 million in Online segment Revenue, with a significant majority coming from personalized doses. However, subsequent events (mentioned below) reveal that the defendants failed to disclose that the platform had started engaging in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Plaintiffs' Arguments The plaintiffs maintain that the defendants deceived investors by lying and withholding critical information about the business practices and prospects during the Class Period. Importantly, the defendants are accused of misleading investors about their illegal practices used to boost Online sales, as well as the potential termination of their contract with Novo Nordisk. The information became clear before the market opened on June 23, 2025, when Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers. Novo Nordisk stated that it was ending the collaboration because Hims & Hers had engaged in dishonest promotional tactics and sold illegitimate, copycat versions of Wegovy, thereby putting patient safety at risk. Moreover, Novo Nordisk explained that HIMS 'failed to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of personalization.' Following the news, HIMS stock collapsed by 34.6% that same day. To conclude, the defendants misled investors by engaging in deceptive and illegal practices to boost Online sales, which ultimately led to the termination of their lucrative contract with Novo Nordisk. Despite these issues, HIMS stock has surged over 108% so far this year.
Yahoo
2 hours ago
- Yahoo
People may start to regain weight within weeks of discontinuing weight loss drugs, study finds
Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a new study finds. The research review, published on Tuesday in the journal BMC Medicine, assessed data from 11 previous clinical trials, involving nearly 2,500 people, and found a broad trend of patients regaining lost weight after their medication courses concluded. At least six drugs have so far been approved for treating obesity in adults – orlistat, naltrexone-bupropion, semaglutide, liraglutide, tirzepatide, and phentermine-topiramate. Six of the 11 clinical trials covered in the review focused on semaglutide, the active ingredient of Ozempic and Wegovy. While a growing body of research shows that prolonged use of these anti-obesity drugs can lead to significant weight loss in adults, preliminary studies indicate weight regain after their discontinuation. 'The long-term change of weight after discontinuation of AOMs is still lacking systematic evaluation,' the new review notes, referring to anti-obesity medications. Initially given to patients with obesity and type 2 diabetes, semaglutide is now sold off-label as a quick fix for weight loss. Researchers, including from the Peking University People's Hospital in China, have now found that while semaglutide and similar medications could lead to significant weight loss in use, a weight rebound could start barely eight weeks after their discontinuation. Representational. A pharmacy owner speaks with a customer at a pharmacy in Pristina (AFP via Getty) In the review, researchers analysed data from 1,574 participants in treatment groups and 893 in control groups across 11 clinical trials, which measured weight change by tracking body weight and BMI after stopping medication. Researchers controlled for contributing factors, including medication type, presence of diabetes, and presence or absence of lifestyle changes like diet or exercise. The analysis found that the weight rebound continued for an average of 20 weeks after discontinuation before plateauing. 'Significant weight regain occurred eight weeks after discontinuation of AOMs and was sustained through 20 weeks,' they write in the review. Participants experienced significant periods of weight regain at eight, 12, and 20 weeks after stopping the drugs, the study found. The weight rebound seemed to depend on factors like the type of medication taken and the consistency of lifestyle change. For instance, patients who completed a 36-week treatment of weight-loss drug tirzepatide regained almost half the weight previously lost after switching to a placebo. The review calls for more studies with longer follow-up periods to further assess potential factors linked to weight change after halting treatment with such drugs.
